Antiproliferative effect of sphingosylphosphorylcholine in thyroid FRO cancer cells mediated by cell cycle arrest in the G2/M phase

Molecular and Cellular Endocrinology

Volumn 274, Issue 1-2, 2007, Pages 43-52

  Afrasiabi, Emad ^a   Blom, Tomas ^a,b   Balthasar, Sonja ^a   Törnquist, Kid ^a,c  

^a ÅBO AKADEMI UNIVERSITY   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

Author keywords

Cancer; Cell cycle; Lipids; Receptors; Thyroid

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; CASPASE 3; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P21; SODIUM; SPHINGOSYLPHOSPHORYLCHOLINE; WORTMANNIN;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THYROID CANCER;

EID: 34547174272     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2007.05.016     Document Type: Article

References (38)

1. Afrasiabi E., Blom T., Ekokoski E., Tuominen R.K., and Tornquist K. Sphingosylphosphorylcholine enhances calcium entry in thyroid FRO cells by a mechanism dependent on protein kinase C. Cell. Signal. 18 (2006) 1671-1678
2. Agrawal S., Agarwal M.L., Chatterjee-Kishore M., Stark G.R., and Chisolm G.M. Stat1-dependent, p53-independent expression of p21(waf1) modulates oxysterol-induced apoptosis. Mol. Cell. Biol. 22 (2002) 1981-1992
3. Balthasar S., Samulin J., Ahlgren H., Bergelin N., Lundqvist M., Toescu E.C., Eggo M.C., and Tornquist K. Sphingosine 1-phosphate receptor expression profile and regulation of migration in human thyroid cancer cells. Biochem. J. 398 (2006) 547-556
4. Barboule N., Lafon C., Chadebech P., Vidal S., and Valette A. Involvement of p21 in the PKC-induced regulation of the G2/M cell cycle transition. FEBS Lett. 444 (1999) 32-37
5. Beil M., Micoulet A., von Wichert G., Paschke S., Walther P., Omary M.B., Van Veldhoven P.P., Gern U., Wolff-Hieber E., Eggermann J., Waltenberger J., Adler G., Spatz J., and Seufferlein T. Sphingosylphosphorylcholine regulates keratin network architecture and visco-elastic properties of human cancer cells. Nat. Cell Biol. 5 (2003) 803-811
6. Bjorklund S., Palmberg S., Rask S., Westerdahl A.C., and Tornquist K. Effects of sphingosine 1-phosphate on calcium signaling, proliferation and S1P2 receptor expression in PC Cl3 rat thyroid cells. Mol. Cell. Endocrinol. 231 (2005) 65-74
7. Boguslawski G., Lyons D., Harvey K.A., Kovala A.T., and English D. Sphingosylphosphorylcholine induces endothelial cell migration and morphogenesis. Biochem. Biophys. Res. Commun. 272 (2000) 603-609
8. + efflux in the activation of apoptosis. J. Biol. Chem. 272 (1997) 32436-32442
9. + influx is required for volume loss during programmed cell death. J. Biol. Chem. 278 (2003) 39176-39184
10. Clair T., Aoki J., Koh E., Bandle R.W., Nam S.W., Patazynska M.M., Mills G.B., Schiffman E., Loitta L.A., and Stracke M.L. Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration sphingosine-1-phosphate. Cancer Res. 63 (2003) 5446-5453
11. Clark J.A., Black A.R., Leontieva O.V., Frey M.R., Pysz M.A., Kunneva L., Woloszynska-Read A., Roy D., and Black J.D. Involvement of the ERK signaling cascade in protein kinase C-mediated cell cycle arrest in intestinal epithelial cells. J. Biol. Chem. 279 (2004) 9233-9247
12. Damia G., and Broggini M. Cell cycle checkpoint proteins and cellular response to treatment by anticancer agents. Cell Cycle 3 (2004) 46-50
13. Desai N.N., Carlson R.O., Mattie M.E., Olivera A., Buckley N.E., Seki T., Brooker G., and Spiegel S. Signaling pathways for sphingosylphosphorylcholine-mediated mitogenesis in Swiss 3T3 fibroblasts. J. Cell Biol. 121 (1993) 1385-1395
14. Fagin J.A., Matsuo K., Karmakar A., Chen D.L., Tang S.H., and Koeffler H.P. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest. 91 (1993) 179-184
15. Goparaju S.K., Jolly P.S., Watterson K.R., Bektas M., Alvarez S., Sarkar S., Mel L., Ishii I., Chun J., Milstien S., and Spiegel S. The S1P2 receptor negatively regulates platelet-derived growth factor-induced motility and proliferation. Mol. Cell. Biol. 25 (2005) 4237-4249
16. + suppresses the activation of apoptosis in lymphocytes. J. Biol. Chem. 272 (1997) 30567-30576
17. Ignatov I., Lintzel J., Hermans-Borgmeyer I., Kreienkamp H.J., Joost P., Thomsen S., Methner A., and Schaller H.C. Role of the G protein-coupled receptor GPR12 as high-affinity receptor for sphingosylphosphorylcholine and its expression and function in brain development. J. Neurosci. 23 (2003) 907-914
18. Ikeda H., Satoh H., Yanase M., Inoue Y., Tomiya T., Arai M., Tejima K., Nagashima K., Maekawa H., Yahagi N., Yatomi Y., Sakurada S., Takuwa Y., Ogata I., Kimura S., and Fujiwara K. Antiproliferative property of sphingosine 1-phosphate in rat hepatocytes involves activation of Rho via Edg-5. Gastroenterology 124 (2003) 459-469
19. Katayama K., Fujita N., and Tsuruo T. Akt/protein B-dependent phosphorylation and inactivation of WEE1Hu promote cell cycle progression at G2/M transition. Mol. Cell. Biol. 25 (2005) 2725-2737
20. Kim K.S., Ren J., Jiang Y., Ebrahem Q., Tipps R., Cristina K., Xiao Y.J., Qiao J., Taylor K.L., Lum H., Anand-Apte B., and Xu Y. GPR4 plays a critical role in endothelial cell function and mediates the effects of sphingosylphosphorylcholine. FASEB J. 19 (2005) 819-821
21. Lee S.R., Park J.H., Chung C.H., Kang S.S., and Bang O.S. Akt-induced promotion of cell-cycle progression at G2/M phase involves upregulation of NF-Y binding activity in PC12 cells. J. Cell Physiol. 205 (2005) 270-277
22. Liang J., and Slingerland J.M. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2 (2003) 339-345
23. Liliom K., Sun G., Bunemann M., Virag T., Nusser N., Baker D.L., Wang D.A., Fabian M.J., Brandts B., Bender K., Eickel A., Malik K.U., Miller D.D., Desiderio D.M., Tigyi G., and Pott L. Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors. Biochem. J. 355 (2001) 189-197
24. Menu E., Kooijman R., Van Valckenborgh E., Asosingh K., Bakkus M., Van Camp B., and Vanderkerken K. Specific roles for the PI3K and the MEK-ERK pathway in IGF-1-stimulated chemotaxis VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model. Br. J. Cancer 90 (2004) 1076-1083
25. Mogi C., Tomura H., Tobo M., Wang J.Q., Damirin A., Kon J., Komachi M., Hashimoto K., Sato K., and Okajima F. Sphingosylphosphorylcholine antagonizes proton-sensing ovarian cancer G-protein-coupled receptor 1 (OGR1)-mediated inositol phosphate production and cAMP accumulation. J. Pharmacol. Sci. 99 (2005) 160-167
26. + exchange. Biochem. Biophys. Res. Commun. 19 (1999) 812-815
27. + system in FRTL-5 thyroid cells: possible involvement of guanosine triphosphate-binding proteins in the lipid signaling. Endocrinology 138 (1997) 220-229
28. Seufferlein T., and Rozengurt E. Sphingosylphosphorylcholine activation of mitogen-activated protein kinase in Swiss 3T3 cells requires protein kinase C and a pertussis toxin-sensitive G protein. J. Biol. Chem. 270 (1995) 24334-24342
29. Smits V.A., Klompmaker R., Vallenius T., Rijksen G., Makela T.P., and Medema R.H. p21 inhibits Thr161 phosphorylation of Cdc2 to enforce the G2 DNA damage checkpoint. J. Biol. Chem. 275 (2000) 30638-30643
30. Spiegel S., and Milstein S. Sphingosine 1-phosphate, a key cell signaling molecule. J. Biol. Chem. 277 (2002) 25851-25854
31. Taylor W.R., and Stark G.R. Regulation of the G2/M transition by p53. Oncogene 20 (2001) 1803-1815
32. Tornquist K., and Ekokoski E. Effect of sphingosine derivatives on calcium fluxes in thyroid FRTL-5 cells. Biochem. J. 299 (1994) 213-218
33. Tornquist K., Saarinen P., Vainio M., and Ahlström M. Sphingosine 1-phosphate mobilizes sequestered calcium, activates calcium entry, and stimulates DNA synthesis in thyroid FRTL-5 cells. Endocrinology 138 (1997) 4049-4057
34. Wakita H., Matsushita K., Nishimura K., Tokura Y., Furukawa F., and Takigawa M. Sphingophosphorylcholine stimulates proliferation and upregulates cell surface-associated plasminogen activator activity in cultured human keratinocytes. J. Invest. Dermatol. 110 (1998) 253-258
35. Weber G.F., Gaertner F.C., Erl W., Janssen K.P., Blechert B., Holzmann B., Weighardt H., and Essler M. IL-22 mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase. J. Immunol. 177 (2006) 8266-8272
36. Xu Y., Fang X.J., Casey G., and Mills G.B. Lysophospholipids activate ovarian and breast cancer cells. Biochem. J. 309 (1995) 933-940
37. Yamada T., Okajima F., Ohwada S., and Kondo Y. Growth inhibition of human pancreatic cancer cells by sphingosylphosphorylcholine and influence of culture conditions. Cell. Mol. Life Sci. 53 (1997) 435-441
38. Zu Heringdorf D.M., Himmel H.M., and Jakobs K.H. Sphingosylphosphorylcholine-biological functions and mechanisms of action. Biochim. Biophys. Acta 1582 (2002) 178-189